紐約，紐約 / ACCESS Newswire /2025 年 3 月 18 日/ 如果您在 GSK plc 投資中遭受損失並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：
https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&amp;wire=1
或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱地址為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。
<img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/api/iframe.ashx/query-cmVsZWFzZWlkPTEwMDE3NzgmdXJsPWh0dHBzOi8vd3d3LnlvdXR1YmUuY29tL2VtYmVkL1R5bExjc1NFczJN?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="0" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/api/iframe.ashx/query-cmVsZWFzZWlkPTEwMDE3NzgmdXJsPWh0dHBzOi8vd3d3LnlvdXR1YmUuY29tL2VtYmVkL1R5bExjc1NFczJN"/>訴訟： 針對 GSK plc 提起了一項集體訴訟，旨在追回在 2020 年 2 月 5 日至 2022 年 8 月 14 日期間因涉嫌證券欺詐而受到不利影響的股東損失。案件詳情： 根據提交的投訴，被告向投資者表示，GSK 基於當時可用的信息和與監管機構的通信，已將 Zantac 從市場上撤回。GSK 還表示，它正在 “繼續調查 NDMA 的潛在來源”。被告還向投資者保證，“GSK、FDA 和 EMA（歐洲藥品管理局）都獨立得出結論，認為沒有證據表明雷尼替丁治療與患者癌症發展的因果關係”，這些發現與 2019 年前發佈的其他雷尼替丁數據一致。最後，被告聲稱他們無法 “量化或可靠估計責任”。這些陳述在實質上是虛假或具有誤導性的。實際上，GSK 完全清楚 NDMA 的來源，並在撤回 Zantac 之前已經知道近 40 年。

葛蘭素史克

針對葛蘭素史克（GSK plc）提起了一項集體訴訟，指控其在 2020 年 2 月 5 日至 2022 年 8 月 14 日期間對股東進行證券欺詐。遭受損失的投資者被鼓勵在 2025 年 4 月 7 日之前聯繫 Levi & Korsinsky LLP，以討論他們在聯邦證券法下的權利和潛在的賠償。訴訟聲稱 GSK 在關於 Zantac 撤出市場及相關風險方面誤導了投資者。Levi & Korsinsky 在證券訴訟方面有着良好的業績記錄，併為受影響的投資者提供免費的諮詢服務

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / If you suffered a loss on your GSK plc investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
<div class="lb-trans">紐約，紐約 / ACCESS Newswire /2025 年 3 月 18 日/ 如果您在 GSK plc 投資中遭受損失並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：
</div>https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&amp;wire=1
<div class="lb-trans">https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&amp;wire=1
</div>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
<div class="lb-trans">或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱地址為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。
</div><img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/api/iframe.ashx/query-cmVsZWFzZWlkPTEwMDE3NzgmdXJsPWh0dHBzOi8vd3d3LnlvdXR1YmUuY29tL2VtYmVkL1R5bExjc1NFczJN" width="0" original-src="https://app.accessnewswire.com/api/iframe.ashx?releaseid=1001778&amp;url=https%3a%2f%2fwww.youtube.com%2fembed%2fTylLcsSEs2M"/>THE LAWSUIT: A class action securities lawsuit was filed against GSK plc that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022.CASE DETAILS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market &#34;[b] ased on information available at the time and correspondence with regulators.&#34; GSK also stated that it was &#34;continuing with investigations into the potential source of NDMA.&#34; Defendants also assured investors that &#34;GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients,&#34; findings that were &#34;consistent with other ranitidine data published prior to 2019.&#34; Finally, defendants claimed that they could not &#34;quantify or reliably estimate the liability.&#34; These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.WHAT'S NEXT? If you suffered a loss in GSK stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&amp;wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.WHY LEVI &amp; KORSINSKY: Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.CONTACT: Levi &amp; Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171 https://zlk.com/SOURCE: Levi &amp; Korsinsky, LLP View the original press release on ACCESS Newswire <img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTAwMTc3OA" width="0" original-src="https://app.accessnewswire.com/img.ashx?id=1001778"/>
<div class="lb-trans"><img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/api/iframe.ashx/query-cmVsZWFzZWlkPTEwMDE3NzgmdXJsPWh0dHBzOi8vd3d3LnlvdXR1YmUuY29tL2VtYmVkL1R5bExjc1NFczJN" width="0" original-src="https://app.accessnewswire.com/api/iframe.ashx?releaseid=1001778&amp;url=https%3a%2f%2fwww.youtube.com%2fembed%2fTylLcsSEs2M"/></div>訴訟： 針對 GSK plc 提起了一項集體訴訟，旨在追回在 2020 年 2 月 5 日至 2022 年 8 月 14 日期間因涉嫌證券欺詐而受到不利影響的股東損失。案件詳情： 根據提交的投訴，被告向投資者表示，GSK 基於當時可用的信息和與監管機構的通信，已將 Zantac 從市場上撤回。GSK 還表示，它正在 “繼續調查 NDMA 的潛在來源”。被告還向投資者保證，“GSK、FDA 和 EMA（歐洲藥品管理局）都獨立得出結論，認為沒有證據表明雷尼替丁治療與患者癌症發展的因果關係”，這些發現與 2019 年前發佈的其他雷尼替丁數據一致。最後，被告聲稱他們無法 “量化或可靠估計責任”。這些陳述在實質上是虛假或具有誤導性的。實際上，GSK 完全清楚 NDMA 的來源，並在撤回 Zantac 之前已經知道近 40 年。

GSK plc 的投資者應在2025年4月7日之前聯繫 Levi & Korsinsky 討論您的權利 - 葛蘭素史克